Clinical trial shows tumor-starving drug improves survival of mesothelioma

Peter Szlosarek, Professor of Medical Oncology at Queen Mary’s Barts Cancer Institute, presented his team’s results from the ATOMIC-Meso clinical trial in partnership with Polaris Pharmaceuticals, Inc., at the American Association for Cancer Research Annual Meeting. The findings show that the new drug, called ADI-PEG20, extends the median survival of patients compared with current standard treatment. This moves the drug closer to final approval by the US Food and Drug Administration (FDA), an achievement that would represent the first such approval of a new chemotherapy drug for this disease in 15 years.

Leave A Comment

Your email address will not be published. Required fields are marked *